Bio-Manguinhos World Public Health - Bio

Bio-Manguinhos:
Partnership for the world
public health
The Immunobiological Technology Institute - Bio-Manguinhos is the biggest and most modern federal laboratory for R&D and production of immunobiologicals
and IVD reagents in Brazil – the South America’s leading
economy, with a population around 203 million people.
This technical-scientific unit of the centenarian Oswaldo
Cruz Foundation (Fiocruz/MOH) plays a strategic role in
the supplying of a range of pediatric vaccines for around
3 millions of newborns per year, besides biopharmaceuticals and IVD reagents, mostly for the Brazilian public
health system.
Bio-Manguinhos
Immunobiological Technology Institute
CONTACTS
[email protected]
Tel +55 21 3882-9383
Castle of Fiocruz
Bio-Manguinhos presents high performance in the
production sector, as well as in research and development aiming to create new products and technologies,
knowledge and economic benefits to the country.
Besides the autochthonous development with a high
skilled team, the Institute has a vast experience with national and global partnerships for co-development and
technological transfer processes. Currently, Bio-Manguinhos has important public-private partnerships ongoing with a view to the provision of new biotech products
to the population.
Africa
Asia
Central America,
Noth America
and Caribbean
South America
Oceania
Bio-Manguinhos also exports
vaccines prequalified by WHO
for more than 70 countries
worldwide, according to United Nations Agencies request.
Immunobiological Technology Institute | Bio-Manguinhos/Fiocruz
Av. Brasil, 4.365 - Manguinhos - Pavilhão Rocha Lima
CEP: 21040-360, Rio de Janeiro, RJ
www.bio.fiocruz.br | www.facebook.com/BioFiocruz
Pictures: Ascom Bio-Manguinhos / Guido / Peter Ilicciev
Partnerships for the
World Public Health
The Bill & Melinda Gates Foundation established a
strategic alliance to prioritize the development of
solutions for pressing global health issues.
During the 9th Grand Challenges Meeting, the
agreement between the Bill & Melinda Gates Foundation and Bio-Manguinhos was announced for the
production, development and export of the vaccine
protecting against rubella and measles.
The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America,
serviced by the Global Alliance for Vaccines and
Immunization and by institutions of the United Nations (UN). The expectation is 30 million doses per
year to be available in the market from 2017. The
initiative will rely on US$ 1.1 million of the Bill &
Melinda Gates Foundation.
“We’re both optimists. We believe by doing these
things - focusing on a few big goals and working with our partners on innovative solutions we can help every person get the chance to live
a healthy, productive life.” ( text from the letter
written by Bill and Melinda Gates to partners.)
Bill Gates and Melinda Gates
New areas
Brazil
CIPBR
•
•
•
•
Butantan Institute
Federal University of Rio de Janeiro (UFRJ)
Fiocruz Units Molecular Biology Institute of Paraná (IBMP)
USA
•
•
•
•
Chembio
Fraunhofer
Luminex
Bill & Melinda Gates Foundation
England
• GlaxoSmithKline (GSK)
Cuba
• Cimab
• Finlay Institute
• Heber Biotec
Multi-purpose plants Following the Good Manufacturing and Laboratory Practices
The Integrated Centre for Prototypes, Biopharmaceuticals and Reagents for Diagnosis (CIPBR) is one of the
largest investments in innovation and technological
development in the country.
• Modern technology platforms for the large scale production of biopharmaceuticals and reagents for diagnosis to meet the demands of the Ministry of Health.
• 1st pilot plant in Brazil with characteristics of GLP,
GMP and Bio-safety with the aim to bridge the innovation gap, and to support internal and external projects,
both at the national and the international level.
• Platforms with simultaneous and independent operations.
Germany
Santa Cruz Campus I RJ
France
With a planned funding of BR $800 million from the
Ministry of Health, the Bio-Manguinhos New Secondary
Operations Facilities will expand the supply of Immunobiologicals for the entire country. The venture, which will
be built in an area of 580,000 m², is under construction
and will be designed to be one of the most modern biotechnology centres in the world. At the site, 120 million
• Qiagen
• Sanofi Pasteur
ISRAEL
• Protalix
Industrial Biotechnology Center
vaccine vials can be produced annually, in addition to
biopharmaceuticals, according to the product mix.
Integrated Center for Prototypes, Biopharmaceuticals and
Reagents for Diagnosis
With this new biotech centre it will be possible to Incorporate in state-of-the-art technologies and international
Obtain certifications from regulatory Authorities such as
the WHO, the Food and Drug Administration (FDA/USA)
and the European Medicines Agency - which will enable
Immunobiologicals Brazil to supply globally.
•D
iphtheria, Tetanus, Pertussis and Haemophilus influenzae type b
• Haemophilus influenzae type b
• Measles, Mumps and Rubella
• M easles, Mumps, Rubella
and Varicella (MMRV)
• Oral Poliomyelitis
• Inactivated Poliomyelitis
• Rotavirus
• 10-valent Pneumococcal
• Polysaccharide Meningitis AC
• Yellow Fever
EUSÉBIO Campus I Ceará
Plant-based Technology Center
Bio-Manguinhos began to invest in building a new campus for plant-based technologies. The new Plant-based
Technology Center will be located at the Fiocruz Ceará
Campus inside Industrial and Technological Health Pole
in the city of Eusébio. With around 225,000 m², the new
site will have facilities dedicated to host on going and
future partnerships for the development and production of plant-based vaccines and biotherapeutics. The
new site is being designed based on modern bioprocess
technologies, construction strategies, sustainability and
compliance to all GMP, GLP and Biosafety regulations.
Industrial Biotechnology Center
•
•
•
•
Imunoblot DPP® HIV-1/2
DPP ® HIV-1/2
DPP ® Syphilis
DPP ® Canine Leishmaniasis
DPP ® Leptospirosis
Prokaryotic expression
Eukaryotic expression
Conjugation
Plant based
Rapid Tests
Flow Cytometry
Microarrays
Molecular Assays
Biopharmaceuticals
• Monoclonal Antibodies
• Therapeutic Proteins
• Molecular Biology:
• Rapid Test:
Vaccines
IVD Reagents
IVD Reagents
NAT HIV/HCV
Core business
•
•
•
•
Portfolio
Vaccines
perspective
alliance for immunization
Partners
• ELISA/IFA:
Chagas Disease IFA
Canine Leishmaniasis ELISA
Human Leishmaniasis IFA
perspective
Innovation in
global health
Plant-based Technology Center
• Kato-Katz Method:
Helm Test
Biopharmaceuticals
• Interferon alpha 2b
• Erythropoietin
• Alphataliglucerase
www.bio.fiocruz.br

Download Report